CanSino Biologics Inc.

This trial evaluates a new five-component vaccine (Tdcp) designed to protect against diphtheria, tetanus, and pertussis (whooping cough). It includes about 1,820 participants aged 7 and older, who receive either the experimental vaccine or a control vaccine. The study measures ho…

This trial is testing the safety of the Menhycia® vaccine in about 3,000 healthy 3-month-old infants who have not yet received any epidemic meningitis vaccine. The infants will receive three doses of the vaccine at least one month apart, with an optional booster at 12 months of a…

This early-stage trial is testing an experimental vaccine designed to protect people aged 6 and older against diphtheria, tetanus, and pertussis (whooping cough). The study will enroll 180 participants to check the vaccine's safety and how well it triggers an immune response. Som…

This trial is testing an experimental vaccine called Menhycia, designed to protect against four types of meningococcal bacteria (A, C, Y, and W135) that can cause meningitis and bloodstream infections. The study involves about 1,480 healthy adults aged 18 to 55, who will receive …

This trial is testing an experimental vaccine designed to protect against four strains of the bacteria that cause meningococcal meningitis, a serious infection of the brain and spinal cord. The study involves around 840 participants aged 7 to 17, who will receive either the new v…

This trial is testing whether a single dose of an experimental tetanus vaccine is safe and triggers a protective immune response in adults aged 18 and older. Participants will receive either the new vaccine or a control vaccine, and researchers will measure antibody levels and mo…